MAP2K7 and melanoma: Although there are numerous studies on the prognostic value of NLR in advanced melanoma and on the predictive potential of NLR in the treatment with ICI or BRAF/MEK-inhibitors, few studies analyze the prognostic potential of NLR and other blood ratios in localized melanoma stages, especially in patients who did not receive adjuvant ICI or targeted therapy.